# US 2012/0252117 A1 · Optimized messenger rna

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252117 A1
- Document ID: US20120252117A1
- Status: Published application
- Kind: A1
- Application number: 13/085,425
- Filed: 2011-04-12
- Published: 2012-10-04
- Earliest claimed: 1998-09-29
- Inventors: Richard F Selden; Allan M. Miller; Douglas A. Treco
- Web page: https://patentgrep.com/patent/US20120252117A1

## CPC

- C12N 9/6437: {Coagulation factor VIIa (3.4.21.21)}
- C07K 14/755: Factors VIII {, e.g. factor VIII C (AHF), factor VIII Ag (VWF)}
- C12N 9/2465: {acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)}
- C12N 9/644: {Coagulation factor IXa (3.4.21.22)}
- C12N 15/67: General methods for enhancing the expression
- C12Y 304/21022: Coagulation factor IXa (3.4.21.22)
- C07K 2319/50: containing protease site
- C07K 2319/61: containing an enzyme fusion for detection (lacZ, luciferase)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The present invention is directed to a synthetic nucleic acid sequence which encodes a protein wherein at least one non-common codon or less-common codon is replaced by a common codon. The synthetic nucleic acid sequence can include a continuous stretch of at least 90 codons all of which are common codons.

## Claims

### Claim 1

A synthetic nucleic acid sequence which encodes a protein wherein at least one non-common codon or less-common codon has been replaced by a common codon, and wherein the synthetic nucleic acid sequence comprises a continuous stretch of at least 90 codons all of which are common codons, or wherein the synthetic nucleic acid sequence comprises a continuous stretch of common codons, which continuous stretch includes at least 33% or more of the codons in the synthetic nucleic acid sequence, or wherein at least 94% or more of the codons in the sequence encoding the protein are common codons and the synthetic nucleic acid sequence encodes a protein of at least about 90 amino acids in length, and wherein the protein is selected from the group consisting of:
blood clotting factor V, blood clotting factor VII, blood clotting factor X, blood clotting factor XIII; an interleukin; erythropoietin (EPO); calcitonin; growth hormone; insulin; insulinotropin; an insulin-like growth factor; parathyroid hormone; Θ-interferon; K-interferon; a nerve growth factor; FSHΘ; tumor necrosis factor; glucagon; bone growth factor-2; bone growth factor-7 TSH-Θ; CSF-granulocyte; CSF-macrophage; CSF-granulocyte/macrophage; an immunoglobulin; a catalytic antibody; protein kinase C; glucocerebrosidase; superoxide dismutase; tissue plasminogen activator; urokinase; antithrombin III; DNAse; tyrosine hydroxylase; apolipoprotein E; apolipoprotein A-I; a globin; low density lipoprotein receptor; IL-2 receptor; an IL-2 antagonist; alpha-1 antitrypsin; soluble CD4; a protein encoded by a virus; an antigen; a protein which does not occur in nature; glucogen-like peptide-1 (GLP-1); β-glucoceramidase; α-iduronidase; α-L-iduronidase; glucosamine-N-sulfatase; alpha-N-acetylglucosaminidase; acetylcoenzyme A:α-glucosmamide-N-acetyltransferase; N-acetylglucosamine-6-sulfatase; β-galactosidase; N-acetylgalactosamine-6-sulfatase; and β-glucuronidase.

### Claim 2 (depends on 1)

The nucleic acid of claim 1, wherein the number of non-common or less-common codons replaced or remaining is less than 15.

### Claim 3 (depends on 1)

The nucleic acid of claim 1, wherein all of the non-common and less-common codons of the synthetic nucleic acid sequence encoding a protein have been replaced with common codons.

### Claim 4 (depends on 1)

A vector comprising the synthetic nucleic acid sequence of claim 1.

### Claim 5 (depends on 1)

A cell comprising the nucleic acid sequence of claim 1.
